The distinction matters because RWD is abundant but raw; RWE requires study design, analytical methodology, and interpretive discipline to be credible.

The challenge for Medical Affairs leaders isn't access to real-world data. Most large pharmaceutical companies have invested substantially in RWE data assets: claims databases, EHR data partnerships, patient registries. The challenge is the scientific and operational fluency to generate, interpret, and communicate insights from those assets quickly enough to be relevant in competitive and regulatory timelines.

Medical Affairs teams are being asked to deploy RWE across four distinct commercial conversations, each with different audiences, timelines, and evidentiary standards.

A VP of Medical Affairs managing multiple therapeutic areas needs to answer complex scientific questions: How are patients in the real world performing on our treatment compared to what was observed in the clinical trial? What subpopulations are showing differential benefit? These questions require sophisticated data analysis, and they're being asked more frequently than most Medical Affairs data teams can service.